Atria Investments Inc Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Atria Investments Inc lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.8% during the third quarter, Holdings Channel reports. The firm owned 13,065 shares of the biopharmaceutical company’s stock after selling 1,916 shares during the period. Atria Investments Inc’s holdings in Halozyme Therapeutics were worth $748,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of HALO. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after acquiring an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB lifted its position in shares of Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares during the last quarter. Epoch Investment Partners Inc. grew its position in Halozyme Therapeutics by 23.3% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after purchasing an additional 270,579 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Halozyme Therapeutics by 9.7% in the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock valued at $43,002,000 after buying an additional 72,544 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler raised their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, JMP Securities raised their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Price Performance

HALO opened at $42.57 on Tuesday. The firm has a 50-day moving average price of $56.04 and a 200-day moving average price of $53.48. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a market capitalization of $5.42 billion, a price-to-earnings ratio of 14.10, a PEG ratio of 0.42 and a beta of 1.29.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $61.75, for a total transaction of $617,500.00. Following the sale, the senior vice president now owns 168,176 shares in the company, valued at $10,384,868. This represents a 5.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders sold 70,000 shares of company stock worth $4,042,500. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.